Memantine as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial

Abstract

Autism is a neurodevelopmental disorder that causes significant impairment in socialization and communication. It is also associated with ritualistic and stereotypical behaviour. Recent studies propose both hyper-and hypoglutamatergic ideologies for autism. The objective of this study was to assess the effects of memantine plus risperidone in the treatment of children with autism. Children with autism were randomly allocated to risperidone plus memantine or placebo plus risperidone for a 10-wk, double-blind, placebo-controlled study. The dose of risperidone was titrated up to 3 mg/d and memantine was titrated to 20 mg/d. Children were assessed at baseline and after 2, 4, 6, 8 and 10 wk of starting medication protocol. The primary outcome measure was the irritability subscale of Aberrant Behavior Checklist-Community (ABC-C). Difference between the two treatment arms was significant as the group that received memantine had greater reduction in ABC-C subscale scores for irritability, stereotypic behaviour and hyperactivity. Eight side-effects were observed over the trial, out of the 25 side-effects that the checklist included. The difference between the two groups in the frequency of side-effects was not significant. The present study suggests that memantine may be a potential adjunctive treatment strategy for autism and it was generally well tolerated. This trial is registered with the Iranian Clinical Trials Registry (IRCT1138901151556N10; www.irct.ir).

The Use of Medications Approved for Alzheimer’s Disease in Autism Spectrum Disorder: A Systematic Review

“…This study administered memantine (up to 15 mg/day if 10–40 kg; 20 mg/day if over 40 kg) compared to placebo and reported significant improvements on the ABC in irritability ( p  < 0.001), stereotypy ( p  < 0.01), and hyperactivity/non-compliance ( p  < 0.01); side effects were similar in both groups (73). …”

The role of glutamate and its receptors in autism and the use of glutamate receptor antagonists in treatment

“…In a recent study, memantine was examined as an add-on therapy to risperidone, an atypical antipsychotic approved for use in autism. Ghaleiha et al (2013) compared memantine plus risperidone versus placebo plus risperidone in children with autism in a 10-week randomized trial. In this study, significant improvements in the memantine-treated group compared to the risperidone only group were observed in for irritability, stereotyped behaviors and for hyperactivity.…”

Memantine: New prospective in bipolar disorder treatment

“…The combination of memantine and risperidone in the treatment of children with autistic disorders reduces the associated manic-like symptomatology [118] .…”